- BIIB has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $480.2 million.
- BIIB traded 13,662 shares today in the pre-market hours as of 8:35 AM.
- BIIB is up 3.7% today from Friday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BIIB with the Ticky from Trade-Ideas. See the FREE profile for BIIB NOW at Trade-Ideas More details on BIIB: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. BIIB has a PE ratio of 28.9. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for Biogen Idec has been 1.4 million shares per day over the past 30 days. Biogen Idec has a market cap of $72.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.97 and a short float of 1.2% with 1.65 days to cover. Shares are up 9.1% year-to-date as of the close of trading on Friday.